Business
Jemperli positive trial in endometrial cancer
Jemperli positive trial in endometrial cancer.
About this update from Gsk Plc
[{"type":"text","content":"\n \n \n Issued: 2 December 2022, London UK\n \n \n \n \n \n \n Jemperli\n \n \n (dostarlimab) RUBY phase III trial met its primary endpoint in a planned interim analysis in patients with primary advanced or recurrent endometrial cancer\n \n \n \n \n \n \n ·\n Results showed a statistically significant and clinically meaningful improvement in investigator-assessed progression-free survival\n \n \n ·\n RUBY is the only first-line trial to show improvement in progression-free survival for an immuno-oncology therapy in combination with standard-of-care chemotherapy in primary advanced or recurrent endometrial cancer\n \n \n ·\n Regulatory submissions based on the trial results are planned for the first half of 2023\n \n \n \n \n \n \n \n \n \n GSK plc (LSE/NYSE: GSK) today announced positive headline results from the planned interim analysis of Part 1 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase III trial investigating Jemperli (dostarlimab) plus standard-of-care chemotherapy (carboplatin-paclitaxel) followed by Jemperli compared to chemotherapy plus placebo followed by placebo\n in adult patients with primary advanced or recurrent endometrial cancer. The trial met its primary endpoint of investigator-assessed progression-free survival (PFS). It showed a statistically significant and clinically meaningful benefit in the prespecified mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) patient subgroup and in the overall population. A clinically relevant benefit in PFS was also observed in the mismatch repair proficient (MMRp)/microsatellite stable (MSS) patient subgroup.\n \n \n \n \n \n While the overall survival (OS) data were immature at the time of this analysis, a favourable trend was observed in the overall population, including both the dMMR/MSI-H and MMRp/MSS subgroups.\n \n \n \n \n \n The safety and tolerability profile of dostarlimab in the RUBY phase III trial was consistent with clinical trials of similar regimens. The most common treatment-emergent adverse events in patients receiving dostarlimab plus chemotherapy were nausea, alopecia, fatigue, peripheral neuropathy, anaemia, arthralgia, constipation and diarrhoea.\n \n \n \n \n \n \n Hesham Abdullah, Senior Vice President, Global Head of Oncology Development, GSK, said:\n \n \"Patients with primary advanced or recu...